ACTU — Actuate Therapeutics Share Price
0.000.00%
Last trade - 00:00- $174.81m
- $166.57m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1,677.78 | ||
| Price to Tang. Book | 1,677.78 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -4809.59% | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). The Company is developing elraglusib, a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3b, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, which lead to tumor cell survival, growth, migration, and invasion. Its candidate products are Elraglusib Injection and Elraglusib Oral Tablet. Elraglusib is the lead drug in the portfolio and is being evaluated in a randomized Phase II trial in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Elraglusib is designed to act as a mediator of antitumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 16th, 2015
- Public Since
- August 13th, 2024
- No. of Shareholders
- 171
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 19,531,636
- Address
- 1751 RIVER RUN, SUITE 400, FORT WORTH, 76107
- Web
- https://actuatetherapeutics.com/
- Phone
- +1 8479864190
- Auditors
- Crowe LLP
Upcoming Events for ACTU
Similar to ACTU
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the Actuate Therapeutics share price?
As of Today at 19:03 UTC, shares in Actuate Therapeutics are trading at $8.95. This share price information is delayed by 15 minutes.
How has the Actuate Therapeutics share price performed this year?
Shares in Actuate Therapeutics last closed at $8.95 and the price had moved by over the past 365 days. In terms of relative price strength the Actuate Therapeutics share price has matched the S&P500 Index by over the past year.
What are the analyst and broker recommendations for Actuate Therapeutics?
The overall consensus recommendation for Actuate Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Actuate Therapeutics dividend yield?
Actuate Therapeutics does not currently pay a dividend.
Does Actuate Therapeutics pay a dividend?
Actuate Therapeutics does not currently pay a dividend.
When does Actuate Therapeutics next pay dividends?
Actuate Therapeutics does not currently pay a dividend.
How do I buy Actuate Therapeutics shares?
To buy shares in Actuate Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Actuate Therapeutics?
As of the previous close price of $8.95, shares in Actuate Therapeutics had a market capitalisation of $174.81m.
Where are Actuate Therapeutics shares listed?
Here are the trading details for Actuate Therapeutics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ACTU
What kind of share is Actuate Therapeutics?
Based on an overall assessment of its quality, value and momentum Actuate Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Actuate Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Actuate Therapeutics is $20.33. That is 127.15% above the last closing price of $8.95.
Analysts covering Actuate Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.14 for the next financial year.
Find out moreWhat is the trend in the Actuate Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Actuate Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +10.72%.
As of the last closing price of $8.95, shares in Actuate Therapeutics were trading +11.49% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Actuate Therapeutics PE Ratio?
The Actuate Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $8.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Actuate Therapeutics?
We do not have data on Actuate Therapeutics' directors